Medical Research Network GmbH, 1010 Vienna, Austria
Research Article
Cost−effectiveness of Landiolol, an Ultra−short−acting Betablocker, for Treatment of Sepsis Related Tachyarrhythmia in Germany
Author(s): Günther Krumpl and Evelyn Walter*
Background: Sepsis and septic-shock are associated with cardiovascular problems, including tachyarrhythmia, myocardial injury, and changes
in vascular endothelial function that might affect cardiac output with potential fatal outcome. The consequences of sepsis extend well beyond the
acute illness. Tachycardia and new-onset atrial-fibrillation (AF), often treated with less effective agents such as amiodarone, are key prognostic
factors for sepsis and associated with increased use of health-care resources and costs. Early decrease of heart-rate is associated with improved
outcome. The use of β-blockers for managing acute arrhythmias in patients with septic-shock has been described in the literature. Landiolol, an
ultra-short-acting β1-selective adrenergic-receptor-antagonist, is used specifically for the acute management of atrial-fibrilla.. Read More»
DOI:
10.37421/2157-1042.2022.8.161
Pharmacoeconomics: Open Access received 106 citations as per Google Scholar report